Increased dosage of Dyrk1A alters alternative splicing factor (ASF)-regulated alternative splicing of tau in Down syndrome
about
Dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A) modulates serine/arginine-rich protein 55 (SRp55)-promoted Tau exon 10 inclusionDYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down SyndromeDissecting Alzheimer disease in Down syndrome using mouse modelsA genetic cause of Alzheimer disease: mechanistic insights from Down syndromeThe molecular basis of cognitive deficits in pervasive developmental disordersPhosphorylation-mediated regulation of alternative splicing in cancerNeuronal-specific deficiency of the splicing factor Tra2b causes apoptosis in neurogenic areas of the developing mouse brainSpecific CLK Inhibitors from a Novel Chemotype for Regulation of Alternative SplicingDesign and synthesis of a library of lead-like 2,4-bisheterocyclic substituted thiophenes as selective Dyrk/Clk inhibitorsRegulation of the alternative splicing of tau exon 10 by SC35 and Dyrk1ADYRK1A genetic variants are not linked to Alzheimer's disease in a Spanish case-control cohort.Dyrk1A overexpression leads to increase of 3R-tau expression and cognitive deficits in Ts65Dn Down syndrome miceMechanisms of tau-induced neurodegeneration.Cyclic AMP-dependent protein kinase A regulates the alternative splicing of CaMKIIδCytoplasmic retention of protein phosphatase 2A inhibitor 2 (I2PP2A) induces Alzheimer-like abnormal hyperphosphorylation of Tau.The role of DYRK1A in neurodegenerative diseases.Splicing factor SC35 promotes tau expression through stabilization of its mRNA.Cyclic AMP-dependent protein kinase regulates the alternative splicing of tau exon 10: a mechanism involved in tau pathology of Alzheimer disease.Link between DYRK1A overexpression and several-fold enhancement of neurofibrillary degeneration with 3-repeat tau protein in Down syndromeRegulation of alternative splicing of tau exon 10 by 9G8 and Dyrk1ATau in Alzheimer disease and related tauopathies.Down syndrome--recent progress and future prospects.Alzheimer's disease neurofibrillary degeneration: pivotal and multifactorialTau splicing and the intricacies of dementia.Truncation and Activation of Dual Specificity Tyrosine Phosphorylation-regulated Kinase 1A by Calpain I: A MOLECULAR MECHANISM LINKED TO TAU PATHOLOGY IN ALZHEIMER DISEASE.Down's-syndrome-related kinase Dyrk1A modulates the p120-catenin-Kaiso trajectory of the Wnt signaling pathwayMolecular and cellular alterations in Down syndrome: toward the identification of targets for therapeuticsIntracellular distribution of differentially phosphorylated dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A).Activation, regulation, and inhibition of DYRK1A.MNB/DYRK1A as a multiple regulator of neuronal development.Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?Alzheimer disease therapeutics: focus on the disease and not just plaques and tanglesRegulation of alternative splicing of tau exon 10.An SRp75/hnRNPG complex interacting with hnRNPE2 regulates the 5' splice site of tau exon 10, whose misregulation causes frontotemporal dementia.Tau and neurodegenerative disease: the story so far.DYRK1A inhibition as potential treatment for Alzheimer's disease.Tau mis-splicing in the pathogenesis of neurodegenerative disorders.Heterogeneous nuclear ribonucleoprotein E3 modestly activates splicing of tau exon 10 via its proximal downstream intron, a hotspot for frontotemporal dementia mutations.Protein kinase a-dependent phosphorylation of serine 119 in the proto-oncogenic serine/arginine-rich splicing factor 1 modulates its activity as a splicing enhancer proteinHydroxybenzothiophene Ketones Are Efficient Pre-mRNA Splicing Modulators Due to Dual Inhibition of Dyrk1A and Clk1/4
P2860
Q24339549-CB7E4591-F373-401B-8570-0B1B031772BBQ26745413-F7851AF4-0759-4C4D-8C1B-955EF2C022CEQ26777254-C84F283F-E153-4118-8E70-00B0C16C9FD9Q26798983-E48013AE-CA29-432A-8D7D-5154F69F7319Q26991872-2D8F994E-C0CF-4639-9C7B-A1989409D0B5Q27009883-47D88EFD-5C46-402C-8B27-9653A620F92FQ27321571-54B3B4F4-B6C1-4B7C-9A1B-04496B07A828Q27666758-070DC4AE-5323-4AD4-AAC1-F4ECFBEB2ED0Q28541616-68EB0033-E5B0-4CC7-BC2F-AB30F5811597Q28592850-4897BB96-75CC-4FBA-8009-2F1BA91946C6Q30967631-F520717A-72DC-4B98-BFBA-F0748EFDF21BQ33674369-127C374D-7F74-4E2D-B241-B024EF2C7F81Q33859830-CFAE3A82-E4C4-42C4-9B8A-92C005909FBAQ34087577-01388129-FFD7-4886-BF5A-E0CC31ACC1B3Q34283467-3875DD10-7967-4E94-9B34-76013A6CEF03Q34642120-B6C0FEB9-2C60-4B27-AF17-3A8C24EEAF61Q34764464-6C029470-E8D4-41D6-84E1-549A27362BD1Q34800508-4A3E11C5-C855-4A3A-BE47-85F1311B3F08Q34867587-85558CD2-949B-424F-B646-FCE63B3E5FEDQ34900413-9DBC19AC-050A-4225-9D7E-5E2198FFBB2DQ34953869-F7F3A0D5-F872-4655-801C-D6862465E75FQ34964947-94B31870-BCA6-4FA6-A224-09D794893504Q34974083-845630A7-292D-450D-9D5A-72F1EF38E8BFQ35226142-8AE452A6-2238-4D23-86B0-9DEB6DEDC420Q35721878-691B6075-1800-4A92-9DB5-2E890B9F35DCQ36010008-C5CD7912-EBF1-4278-AE4B-6897EBB4CD5CQ36111546-82F53D22-EE2D-477F-A171-9DBD8D66E695Q37633160-4CE9CED7-A16D-43DD-A674-2B5677923EDAQ37815234-E8AA0EB8-89E4-4713-875E-E734C55B8BD2Q37820722-466D18A1-0D8B-48B3-BC61-9E4D5FD47BFEQ38061634-72A843B6-BC3B-4AA8-94B6-67A2B8F12B2CQ38177975-FB162DDB-E3A0-4D13-A44E-9068F25BC220Q38195811-8DE21B7F-55C0-4D5E-9425-653C6017B5ACQ38270739-9701A94E-A75E-4E00-AA1A-1385DDC60141Q38658752-FD0E143D-BF44-484E-ACFB-400C1B4001ECQ38807264-2AFD6C00-8A44-4DFD-81D6-FA2DF2F35456Q38843730-68F9EED7-3477-4F36-9697-5E0887BC022AQ39774444-8D077EC7-6C09-4FB0-8F7B-2231D9505A4CQ41094983-0DA25FEA-0FE6-4590-B31B-2814E4D431C9Q41739576-32ECC3CB-7B62-412F-9320-F34C3AFB050A
P2860
Increased dosage of Dyrk1A alters alternative splicing factor (ASF)-regulated alternative splicing of tau in Down syndrome
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Increased dosage of Dyrk1A alt ...... licing of tau in Down syndrome
@en
Increased dosage of Dyrk1A alters alternative splicing factor
@nl
type
label
Increased dosage of Dyrk1A alt ...... licing of tau in Down syndrome
@en
Increased dosage of Dyrk1A alters alternative splicing factor
@nl
prefLabel
Increased dosage of Dyrk1A alt ...... licing of tau in Down syndrome
@en
Increased dosage of Dyrk1A alters alternative splicing factor
@nl
P2093
P2860
P50
P356
P1476
Increased dosage of Dyrk1A alt ...... licing of tau in Down syndrome
@en
P2093
Chunlei Zhou
Jerzy Wegiel
Jianhua Shi
Jianhua Zhou
Khalid Iqbal
Tianyi Zhang
Xiaosong Gu
Yu-Wen Hwang
P2860
P304
28660-28669
P356
10.1074/JBC.M802645200
P407
P577
2008-07-24T00:00:00Z